Roche to present ophthalmology portfolio data at ARVO 2026
- Roche will present >45 abstracts, including 20 oral presentations, at ARVO 2026 (3–7 May) across five retinal conditions.
- VOYAGER (NCT05476926) real‑world OCT analysis shows six months of faricimab (Vabysmo) reduced retinal fluid and improved anatomy in treatment‑naïve and previously treated nAMD and DME patients.
- Susvimo (Port Delivery Platform with ranibizumab) data from Pagoda, Belvedere and PK simulations indicate sustained intraocular delivery with potential to lower injection burden.
- Vamikibart, an intravitreal IL‑6 inhibitor, showed early efficacy/safety in phase I and is progressing through phase II (ALLUVIUM, BARDENAS) and phase III (MEERKAT, SANDCAT) programs.
ARVO 2026 program
Roche will present over 45 abstracts at ARVO (3–7 May), including 20 oral presentations across five retinal conditions: geographic atrophy, retinal vein occlusion, uveitic macular edema, diabetic macular edema and neovascular age‑related macular degeneration.
Vabysmo (faricimab) real‑world findings
VOYAGER (NCT05476926) used a deep‑learning analysis of OCT images to show six months of faricimab reduced retinal fluid and improved retinal anatomy in both treatment‑naïve and previously treated nAMD and DME patients; related presentations include 1‑ and 2‑year outcomes, automated fluid quantification versus aflibercept, and a TENAYA/LUCERNE post‑hoc analysis on subretinal hyperreflective material volume.
Susvimo (Port Delivery Platform with ranibizumab)
Data from Pagoda, Belvedere and model‑based pharmacokinetic simulations describe sustained intraocular ranibizumab delivery, comparisons of retinal fluid, thickness and leakage versus intravitreal injections in bilateral DME, patient preference at year‑2 and interim summaries for eyes with high injection burden.
Vamikibart (IL‑6 inhibitor)
Phase I DOVETAIL reported rapid vision gains and macular edema resolution in uveitic macular edema with no treatment‑related serious adverse events; vamikibart is being evaluated in phase II ALLUVIUM and BARDENAS (including combination with ranibizumab) and in phase III MEERKAT and SANDCAT studies.
Source: Roche